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ABSTRACT
Bacterial topoisomerase I is a potential target for
discovery of new antibacterial compounds. Mutant
topoisomerases identified by SOS induction screen-
ing demonstrated that accumulation of the DNA
cleavage complex formed by type IA topoisome-
rases is bactericidal. Characterization of these
mutants of Yersinia pestis and Escherichia coli
topoisomerase I showed that DNA religation can
be inhibited while maintaining DNA cleavage activity
by decreasing the binding affinity of Mg(II) ions. This
can be accomplished either by mutation of the
TOPRIM motif involved directly in Mg(II) binding or
by altering the charge distribution of the active site
region. Besides being used to elucidate the key ele-
ments for the control of the cleavage-religation
equilibrium, the SOS-inducing mutants of Y. pestis
and E. coli topoisomerase I have also been utilized
as models to study the cellular response following
the accumulation of bacterial topoisomerase I
cleavage complex. Bacterial topoisomerase I is
required for preventing hypernegative supercoiling
of DNA during transcription. It plays an important
role in transcription of stress genes during bacterial
stress response. Topoisomerase I targeting poisons
may be particularly effective when the bacterial
pathogen is responding to host defense, or in the
presence of other antibiotics that induce the bacte-
rial stress response.
INTRODUCTION
Topoisomerases catalyze the interconversion of DNA
topological isomers via coupling of DNA phosphodiester
bond cleavage and religation with the passage of DNA
through the break. By maintaining global DNA supercoil-
ing at optimal level and removing local topological
barriers, DNA topoisomerases play vital roles in DNA
replication, transcription, repair and recombination (1).
Topoisomerases are divided into diﬀerent subfamilies
based on their mechanisms and sequence similarities
(2–4). Type I topoisomerases cleave and rejoin one
strand of DNA while type II topoisomerases cleave and
rejoin a double strand of DNA during catalysis. Human
topo IB, IIA and bacterial topo IIA enzymes are well
utilized clinical targets for anticancer and antibacterial
chemotherapy (5–9). These topoisomerase targeting com-
pounds initiate the cell killing process by either stabilizing
or increasing the accumulation of the covalent complex
formed between the enzyme and cleaved DNA and are
called ‘topoisomerase poisons’ (9–11). Compounds that
interact with type IA topoisomerases with high speciﬁcity
to increase the level of the covalent complex remain to be
identiﬁed. The emergence of bacterial pathogens resistant
to multiple antibacterial drugs in both the hospital and
community setting is a serious global public health pro-
blem, presenting an urgent need for discovery of new
classes of antibacterial compounds. Based on the simila-
rities in the topoisomerase mechanisms, it should be pro-
ductive to identify small molecules that can act as poisons
of bacterial type IA topoisomerases.
TYPE IA TOPOISOMERASES BACTERIA
There is at least one type IA topoisomerase found in each
bacterial genome (12). Topo I is present in all bacteria and
is the major activity responsible for removal of excess neg-
ative supercoiling (13). In Escherichia coli, the promoters
of topo I and gyrase genes are under homeostatic control
by DNA supercoiling to maintain the global level of
supercoiling (14,15). Topo III is found in only some
of the bacterial genomes. In vitro it is much more eﬃcient
in catalyzing DNA decatenation reaction than relaxation
(13). Escherichia coli topo III has been proposed to play a
role in resolving RecQ associated recombination inter-
mediates (16). Transposon insertion or deletion mutants
in the topA gene coding for topo I could be isolated from
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(17–20). Attempts to isolate transposon insertion mutants
in the topA gene were unsuccessful in Mycobacterium
tuberculosis and Helicobacter pylori (21,22) suggesting
that topo I might be essential in these bacteria. This
should be further investigated by additional genetic stud-
ies. In E. coli, topo III is also not essential but absence of
both type IA topoisomerases resulted in chromosomal
segregation defect (23). It was proposed that a type IA
topoisomerase activity is required in general for resolving
recombination intermediates involving single strand DNA
passage (1). A broad spectrum type IA topoisomerase
poison that can act on both topo I and topo III would
have a target always present in any bacteria.
Even though E. coli topA mutants are viable, growth at
low temperature requires topo I function (24,25). During
transcription, the movement of the RNA polymerase
complex generates positive supercoils in the DNA tem-
plate ahead of it and negative supercoils behind it (26).
Topo I activity is needed for removal of the negative
supercoils to prevent hypernegative supercoiling and R-
loop formation (27,28). The importance of topo I function
in transcription is also illustrated by the direct protein–
protein interaction between E. coli topo I and RNA poly-
merase (29,30).
FUNCTION OF BACTERIAL TOPOISOMERASE I IN
STRESS RESPONSE AND PATHOGENESIS
The role of topo I in relaxation of transcription-induced
negative supercoiling is probably especially important
during stress response when a large number of stress
genes have to be induced rapidly for survival (31).
Transcription of E. coli topA gene is under control of mul-
tiple promoters recognized by s32, s38 in addition to s70
(32,33). Besides these alternative s factors, topA transcrip-
tion is also regulated by binding of Fis to the promoter
region (34). Topo I function and regulation have been
shown to be important for E. coli response to high tem-
perature and oxidative stress (35–38). RNase H overpro-
duction can partially restore the s32–dependent stress
genes transcription defect in the absence of topA, indicat-
ing that R-loop formation from hypernegative supercoil-
ing at heat shock genes loci is responsible for the eﬀect of
the topA mutation. The response to high temperature and
oxidative stress is an important element of bacterial patho-
gen adaptation against host defense. In H. pylori, the topA
gene has been shown to be up-regulated by prolonged acid
exposure (39). Loss of topo I function in E. coli aﬀects
transcription of the acid resistance genes gadA and gadBC
involving a mechanism independent of R-loop suppres-
sion (40). It was shown recently that a pathway of s38
stress response involves unwrapping of the poised inactive
transcription complex by DNA relaxation to allow activa-
tion (41). The relaxing activity of topo I may play a role
via this mechanism in the activation of some of the pro-
moters that are stimulated by DNA relaxation (42,43).
The important role of topo I in bacterial stress response
and pathogenesis implies that if topo I activity is reduced
as a defensive adaptation for an antibiotic acting as type
IA topoisomerase poison, the ability of the pathogen to
survive in the host environment may be compromised.
Bacterial genes related to pathogenesis and virulence
have been shown to be sensitive to topA mutation. These
include the fooB gene for ﬁmbriae F1651 in pathogenic
E. coli 4787 (44) and the thermally regulated invasive
genes of S. ﬂexneri (20). The invA gene of S. typhimurium
was poorly expressed in a topA mutant, and this correlated
with the ability of S. typhimurium to penetrate tissue cul-
ture cells (45). Signature-tagged transposon mutagenesis
has identiﬁed topA to be one of the genes aﬀecting survival
of Yersinia enterocolitica in animal host (46). In addition,
topA gene was among those found to be highly expressed
by avian pathogenic E. coli (APEC) in infected tissues
(47).
The lethal mechanism of many bactericidal antibiotics
based on diﬀerent mechanisms of action, including quino-
lones and ampicillin, have been shown to involve at least
in part the formation of reactive oxygen species (48–50).
Since bacteria in general would respond to such antibac-
terial antibiotics with transcription of stress regulons, topo
I is expected to interact extensively with negatively super-
coiled DNA at the induced transcription loci, and provide
additional opportunity for the topo I cleavage complex to
be trapped by an inhibitor. Topo I inhibitors that act as
poisons may therefore be particularly eﬀective in combi-
nation therapy with other antibiotics.
CELL KILLING BY BACTERIAL TOPOISOMERASE
I MUTANTS THAT ACCUMULATE THE COVALENT
CLEAVAGE COMPLEX
Since molecules that can act eﬀectively as bacterial topo I
poisons have not been previously identiﬁed, it is important
to demonstrate that trapping of topo I cleavage complexes
on single-stranded DNA will indeed lead to bacterial cell
death, just as tapping of type IIA topoisomerases on
double-stranded DNA would. This would validate the tar-
geting of bacterial topo I in the search for novel antibac-
terial compounds. It is known from previous work that
the SOS response of E. coli is induced by the trapping of
gyrase cleavage complex by quinolones (51). Topo I muta-
tions that mimic the action of a topoisomerase poison and
result in increased accumulation of the cleavage complex
may be expected to also induce the SOS response. The
isolation of such topo I mutants was achieved by screening
for SOS-inducing recombinant mutant Yersinia pestis
topo I expressed in E. coli under the control of the
tightly-regulated BAD promoter (52). A pool of mutagen-
ized plasmid pYTOP expressing random mutants of
Y. pestis topo I was ﬁrst isolated in the presence of 2%
glucose to suppress the expression of any potentially lethal
mutant that accumulate the cleavage complex. The muta-
genized plasmid was then transformed into E. coli JD5
strain with dinD1::lacZ fusion. Induction of the DNA
damage SOS response would result in synthesis of b-galac-
tosidase from activation of the dinD1 promoter and for-
mation of blue colonies on Xgal plate. SOS-inducing
Y. pestis topo I mutants were identiﬁed in such blue colo-
nies in the presence of low concentration of arabinose
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inducing mutant topo I with high concentration of arabi-
nose resulted in  4 logs loss of viable counts after 2h (52).
The mutation responsible for this phenotype was identi-
ﬁed to be a Gly to Ser substitution in the TOPRIM motif
DxDxxG conserved in nucleotidyl transferases (53).
Mutant topoisomerase with this Gly to Ser substitution
was found to be defective in DNA rejoining after forma-
tion of the covalent DNA cleavage complex (52). This
result demonstrated that accumulation of the covalent
cleavage complex of bacterial topo I could indeed lead
to rapid bacterial cell death and validated bacterial type
IA topoisomerases as useful targets for discovery of novel
bactericidal compounds. The Gly to Ser mutation was the
only substitution found at that position to have the SOS-
inducing and cell killing phenotypes for Y. pestis topo I.
The other more bulky substitutions eliminated DNA
cleavage activity. A Met to Val substitution immediately
following the active site tyrosine was present in the orig-
inal SOS inducing mutant (52) and was found to enhance
DNA cleavage without inhibiting DNA religation (54).
Mg
2+ ions are required for DNA rejoining and DNA
relaxation by type IA topoisomerases (13,55). The aspar-
tates in the TOPRIM motif DxDxxG in E. coli topo I have
been shown to coordinate two Mg
2+ ions(56). Mg
2+ bind-
ing by the TOPRIM motif is found to be critical for the
DNA cleavage-religation equilibrium of bacterial topo I.
Characterization of the SOS-inducing and cell killing
topo I mutants demonstrated that there are at least three
mechanisms of decreasing Mg
2+ binding aﬃnity and
inhibiting DNA religation (Figure 1). The Gly to Ser muta-
tion at the TOPRIM motif probably distorted the structure
of the TOPRIM domain as the ﬁrst mechanism of perturb-
ing DNA cleavage-religation. Replacement of the con-
served Met adjacent to the active site tyrosine with Arg
also resulted in reduced Mg
2+ binding, inhibition of
DNA religation and the cell killing phenotype. Molecular
modeling was in agreement with increased positive charge
in the active site region due to the substitution of the neu-
tral Met with the positively charged Arg (57). The change
in electrostatic potential in theactive site provided asecond
mechanism of perturbing Mg
2+ binding and DNA cleav-
age-religation. It is also expected that interfering with
the metal-ligand interaction directly would provide a
third mechanism of perturbing Mg
2+ binding and DNA
cleavage-religation. Results from our recent experiments
showed that an Asn substitution at the ﬁrst TOPRIM
motif Asp residue gave rise to an extremely toxic topo I
mutant, and the Asn substitution at the second TOPRIM
motif Asp residue also resulted in a mutant that was lethal
when induced (B. Cheng et al., manuscript in preparation).
While the involvement of Mg
2+ ions is widely found in
many cellular catalytic mechanisms, there is precedence
for small molecules aﬀecting Mg
2+ interactions being
identiﬁed as speciﬁc inhibitors of a cellular process
which have been approved in human therapy. HIV-1 inte-
grase is an important new target for anti-viral therapy for
cases resistant to existing drugs against HIV-1 reverse
transcrptase and protease (58,59). The integrase mecha-
nism is similar to the type IA topoisomerase mechanism
in the use of two aspartates and one glutamate (56)
to coordinate two divalent ions and bring about protein
conformational change (60–62). Small molecules that
can chelate the divalent ions in the HIV-1 integrase
active site have been identiﬁed and one, raltegravir has
been approved for treatment of AIDS patients (63,64).
Therefore it is not unreasonable to expect that it may be
possible to inhibit the interaction between bacterial topo I
and metal ions in the active site with a small molecule and
achieve accumulation of the DNA cleavage complex for
antibacterial therapy.
While the TOPRIM motif and surrounding residues
around the active site tyrosine (Figure 1) have been iden-
tiﬁed to be important for controlling DNA cleavage/reli-
gation, other regions of the bacterial topo I protein could
also aﬀect the level of accumulation of the covalent cleav-
age complex. Subdomain III with the 50phosphate of the
cleaved DNA bound covalently to the active site tyrosine
Y319
M320
D113
D111
G116
Subdomain I
Subdomain III
Subdomain II
Subdomain IV
Figure 1. Structure of the 67kDa N-terminal fragment of E. coli topo I
(PDB ECL1) and the close-up view of the active site showing the
nucleophilic tyrosine Y319 and the residues in the TOPRIM motif
and active site region where mutations can result in cell killing due
to inhibition of Mg
2+ binding and DNA religation.
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enzyme transitioned from the closed structure (Figure 1)
to a more open structure during the catalytic cycle for
DNA strand passage to take place. Subdomain I then
must move back to near its original position before
DNA religation can occur. Mutations or small molecules
that can stabilize the intermediate complex with subdo-
main III separated from subdomains I and IV by aﬀecting
the protein conformational changes could also lead to
increased accumulation of the cleavage complex in vivo
and result in cell killing. It is hopeful that further charac-
terization of the SOS-inducing topo I mutants would iden-
tify regions in the topo I structure that may be potential
binding sites for such small molecules.
CELLULAR RESPONSE TO TOPOISOMERASE I
CLEAVAGE COMPLEX AND THE CELL DEATH
PATHWAY
The bacterial topo I mutants that accumulate the cleavage
complexes were utilized to study the cellular response to
topo I cleavage complex and the repair pathway in E. coli.
The homologous recombination function of RecA was
found to be required for repair of topo I cleavage com-
plex. Induction of the SOS response by the recombination
deﬁcient RecA718 protein was found to be insuﬃcient for
repair of topo I mediated DNA cleavage (65) Quinolones
are known to induce the SOS response of E. coli via the
RecBCD pathway (66). Double-strand DNA breaks and
chromosomal fragmentation occur after trapping of the
cleavage complex between the gyrase A subunits and
both strands of DNA (67,68). Although topo I cleaves
only a single-strand of DNA at a time, RecBCD function
was also found to be required for induction of the SOS
response by RecA (65). The E. coli RecBCD complex
unwinds and degrades DNA at double strand breaks
with free DNA ends until the RecBCD activity is modiﬁed
by encountering a Chi site on DNA. The Chi-modiﬁed
RecBCD nuclease activity generates a 30 single-stranded
overhang and facilitates the assembly of a RecA ﬁlament
on this single-stranded DNA region downstream of the
Chi site (69). Mutations in the single-strand gap repair
pathway genes recF and recR were found to have no
eﬀect on SOS induction or viable colony counts following
accumulation of the topo I cleavage complex (65). It
remains to be determined how the single strand break
covalently linked to topo I protein is converted to a
double strand break with free ends that can be processed
by the RecBCD complex.
The quinolone induced gyrase cleavage complex blocks
DNA replication, but ongoing DNA replication is not
necessary or suﬃcient for the lethal eﬀect of the quino-
lones (11,70). Depending on the structure of the quino-
lone, inhibition of protein synthesis following quinolone
addition by chloramphenicol may or may not oﬀer protec-
tion. This suggests that there is more than one pathway
involved for the lethal action of quinolones (11). It is pos-
sible that a newly synthesized protein may be required for
one of the cell killing pathways. In eukaryotes, Tyr-DNA
phosphodiesterase (Tdp1) activity has been shown to
cleave the linkage between 30 DNA phosphate and type
IB topoisomerases (71,72), and may in addition also be
involved in the processing of the type IIA topoisomerases
linked to the 50 DNA phosphate (73,74). Homologues of
Tdp1 have not been identiﬁed in bacterial genomes so it is
not known if a bacterial Tyr-DNA phosphodiesterase is
available to cleave the linkage between the type IA and
type IIA topoisomerase proteins and the 50 phosphates of
the cleaved bacterial DNA.
INHIBITORS OF BACTERIAL TOPOISOEMRASE I
Even though DNA gyrase is the primary target of quino-
lones in E. coli, certain quinolones including perﬂoxacin,
ciproﬂoxacin, norﬂoxacin and oﬂoxacin have been
shown to inhibit the relaxation activity of E. coli topo I
at concentrations 10-fold or higher of that required to
inhibit the supercoiling activity of E. coli gyrase (75,76).
Nevertheless, E. coli topo I was found to be signiﬁcantly
more sensitive to these quinolones than calf thymus topo-
isomerase I and II.
Inhibition of E. coli topo I by phospholipids has also
been reported (77). The inhibition of the in vitro relaxation
activity by cardiolipin (Figure 2A) could be suppressed by
chlorpromazine. Treatment of E. coli cells with chlorpro-
mazine resulted in relaxation of plasmid DNA that was
dependent on the function of the topA gene. This sug-
gested that chlorpromazine may interfere with the in vivo
interaction between E. coli topo I and phospholipids in
E. coli cells (77).
Escherichia coli Tn5 transposase protein has been
shown to copurify with E. coli topo I and inhibit its relax-
ation activity (78). The titration of topo I activity by over-
expressed Tn5 transposase leads to ﬁlamentation, aberrant
nucleoid segregation and cell death (79). The lethality
from overexpression of Tn5 transposase could be sup-
pressed by chromosomal mutations that increased the
level of topo I protein (80). The N-terminal amino acids
of Tn5 transposase are required for the interaction with
topo I and the resulting lethal eﬀect from Tn5 transposase
overexpression (78,79).
In order to identify small molecules as leads for bacte-
rial topo I poisons, a cell based high-throughput assay was
developed utilizing E. coli cells with enhanced permeabil-
ity to small molecules, and overexpressing Y. pestis topo I
with the dinD1::luxCADBE luciferase fusion as reporter
(81). The goal was to identify small molecules that could
induce higher level of SOS response when wild-type
recombinant topo I was overexpressed as compared
to the recombinant topo I with the active site nucleophile
tyrosine residue substituted with alanine. Three small
molecules (Figure 2B) capable of enhancing bacterial
topo I DNA cleavage and inhibiting the relaxation activity
have been identiﬁed (81). These compounds had antibac-
terial activity against the gram positive Bacillus subtilis but
not E. coli cells with normal permeability, and may not
have the desired speciﬁcity against bacterial topo I (81).
Compound 1 is the natural product stephenanthrine, a
phenanthrene alkaloid. It has structural similarities to
benzo[c]phenanthridines and protoberberine alkaloids
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mammalian topoisomerase I and II (82). Minor groove
binders including the bisbenzimide Hoechst 33342 are
known to exhibit anti-tumor activity due to inhibition of
human topoisomerase I and trapping of the human topo-
isomerase I cleavage complex (83). More recently, modiﬁ-
cation of Hoechst 33342 has provided novel ligands that
could clear bacterial infections from mammalian cell cul-
ture without apparent cytotoxicity to the mammalian
cells, and these ligands preferentially inhibited E. coli
topo I over human topo I in vitro (Vibha Tandon, per-
sonal communications). These results suggest that modiﬁ-
cation of ligand structures can potentially shift their
speciﬁcity from inhibiting mammalian topoisomerase I
towards targeting bacterial topo I, improving their anti-
microbial potential while limiting the cytotoxicity.
FUTURE DIRECTIONS
Additional screenings should be carried out to identify
compounds that can act as topo I poisons so that they
can be developed into leads for new antibacterial therapy.
Two high-throughput assays have been developed assay-
ing DNA supercoiling by DNA gyrase and DNA relax-
ation by eukaryotic topo I and II as well as E. coli topo
IV (84). These assays should be applicable to identifying
small molecules that can inhibit relaxation by bacterial
topo I. Some of the relaxation inhibitors may act by
inhibiting DNA religation and be useful as a bacterial
topo I poison. Other in vitro high-throughput assays
that can directly measure the level of the topo I cleavage
complex would be extremely useful for identifying new
leads.
With sites in bacterial topo I structure important for the
control of the DNA cleavage-religation equilibrium being
located by the SOS-inducing mutations, it should be pos-
sible to identify small molecules that can interact with
these sites in the enzyme. The virtual screening approach
has been used to discover novel gyrase inhibitors (85), and
should be attempted for identifying leads for discovery of
bacterial topo I poisons.
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